Written and peer-reviewed by physicians—but use at your own risk. Read our disclaimer.

banner image

amboss

Trusted medical answers—in seconds.

Get access to 1,000+ medical articles with instant search
and clinical tools.

Try free for 5 days

Neuroblastoma

Last updated: October 18, 2020

Summarytoggle arrow icon

Neuroblastoma is a malignant neuroendocrine tumor of the sympathetic nervous system that originates from neural crest cells. It is the most common extracranial solid malignancy in children and the most common malignancy found in infants. Given its origin, neuroblastoma can occur in any aggregation of sympathetic nervous tissue, including the adrenal glands, the sympathetic chain, and the paraganglia (e.g., the carotid body). The clinical presentation is mainly determined by the site of the primary tumor, if it secretes catecholamines, and whether it has metastasized. In most cases, neuroblastomas stem from the adrenal glands within the abdominal cavity and present as a palpable abdominal mass that can cross the midline. Urine tests for catecholamine metabolites homovanillic acid (HVA) and vanillylmandelic acid (VMA) play an important role in diagnosis. Treatment is determined mainly by patient age at the time of diagnosis, clinical stage, and possible amplification of the MYCN oncogene. The prognosis depends on disease progression and is very good in early stages. Spontaneous remission may occur even in cases of metastatic disease.

Neuroblastoma is a malignant, embryonal neuroendocrine neoplasm of the sympathetic nervous system that originates from neural crest cells; , potentially secretes catecholamines; , and is usually found in the adrenal glands or sympathetic ganglia.
References:[1]

References:[2][3][4][5]

Epidemiological data refers to the US, unless otherwise specified.

References:[3]

General symptoms

Localized symptoms

Location Associated symptoms

Abdomen (in > 60% of cases)

  • Palpable, firm, irregular abdominal mass that may cross the midline (in contrast to Wilms tumor, which is smooth and usually does not cross the midline)
  • Abdominal distension and pain
  • Hepatomegaly
  • Constipation

Chest (in ∼ 20% of cases): particularly paravertebral ganglia

Neck

Orbit of the eye

Bones

Skin

  • Subcutaneous nodules

Paraneoplastic syndromes

References:[7][8][9][10][11][12]

International Neuroblastoma Staging System (INSS) [13]
Stage Definition
1
2A
2B
3
4
  • Any tumor with dissemination to distant lymph nodes or other organs (e.g., bone, liver, skin), with the exception of Stage 4S disease
4S

Laboratory tests

Other procedures

References:[7]

  • Homer Wright rosettes: Halo-like clusters of neuroblast cells surrounding a central pale area containing neuropil (associated with tumors of neuronal origin such as neuroblastoma, medulloblastoma, primitive neuroectodermal tumors, and pineoblastoma)
  • Small round blue cells with hyperchromatic nuclei
  • Bombesin and NSE positive

References:[3][14][15]

The differential diagnoses listed here are not exhaustive.

Neuroblastoma patients are treated based on their risk category (low, intermediate, or high), which is based on the stage of their neuroblastoma (extent of disease), age at diagnosis, and the presence/absence of MYCN amplification.

  • Low risk: generally children with early-stage disease (Stages 1–2) and no MYCN amplification
  • Intermediate risk: generally children with intermediate and late-stage disease (Stages 3–4) and no MYCN amplification
  • High risk: generally children with late-stage disease and/or MYCN amplification
  • Stage 4S (an exception): disseminated disease in infants (< 12 months)
    • Better prognosis than other stage 4 neuroblastoma and spontaneous regression is very common
    • Children with Stage 4S belong to the low-risk or intermediate-risk groups unless they have a MYCN amplification, in which case they are high-risk patients
Treatment of neuroblastoma
Treatment Low-risk neuroblastoma Intermediate-risk neuroblastoma High-risk neuroblastoma
Observation only X
Preoperative chemotherapy (e.g., doxorubicin, cyclophosphamide, etoposide, and a platinum drug) X X X
Surgery X X X
Postoperative chemotherapy X X
Radiation X X
GD2 antibody, dinutuximab, granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin 2 (IL-2), and cis-retinoic acid X
Other postoperative therapies (e.g., MIBG therapy) X

Spinal cord compression requires immediate surgical decompression or chemotherapy to shrink tumor tissue!

References:[16][17][18][19][20]

  • Prognosis depends on the risk group. Important factors include:
    • Age
    • Children with MYCN amplification are classified as high risk
    • Histopathology, disease dissemination and biochemical markers

References:[19][21]

  1. Shohet JM, Nuchtern JG. Epidemiology, Pathogenesis, and Pathology of Neuroblastoma. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. http://www.uptodate.com/contents/epidemiology-pathogenesis-and-pathology-of-neuroblastoma.Last updated: August 19, 2016. Accessed: March 9, 2017.
  2. Ohlsson B, Fredäng N, Axelson J. The effect of bombesin, cholecystokinin, gastrin, and their antagonists on proliferation of pancreatic cancer cell lines. Scand J Gastroenterol. 1999; 34 (12): p.1224-1229. doi: 10.1080/003655299750024742 . | Open in Read by QxMD
  3. Kang J, Ishola TA, Baregamian N, et al. Bombesin induces angiogenesis and neuroblastoma growth. Cancer Lett. 2007; 253 (2): p.273-281. doi: 10.1016/j.canlet.2007.02.007 . | Open in Read by QxMD
  4. Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010; 362 (23): p.2202-2211. doi: 10.1056/nejmra0804577 . | Open in Read by QxMD
  5. SEER Pediatric Monograph - Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995.
  6. What Are the Key Statistics About Neuroblastoma?. https://www.cancer.org/cancer/neuroblastoma/about/key-statistics.html. Updated: January 22, 2016. Accessed: March 9, 2017.
  7. Cancer Facts & Figures 2014: Special Section: Cancer in Children & Adolescents .
  8. Yoshimoto M, Caminada de Toledo SR, Monteiro Caran EM, et al. MYCN Gene Amplification. Am J Pathol. 1999; 155 (5): p.1439-1443. doi: 10.1016/s0002-9440(10)65457-0 . | Open in Read by QxMD
  9. Shohet JM, Nuchtern JG. Clinical Presentation, Diagnosis, and Staging Evaluation of Neuroblastoma. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. http://www.uptodate.com/contents/clinical-presentation-diagnosis-and-staging-evaluation-of-neuroblastoma.Last updated: May 13, 2016. Accessed: February 16, 2017.
  10. Pochedly CE. Neuroblastoma: Tumor Biology and Therapy. CRC Press ; 1990
  11. Opsoclonus-myoclonus syndrome. http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=1183. Updated: November 1, 2014. Accessed: March 9, 2017.
  12. Signs and Symptoms of Neuroblastoma. https://www.cancer.org/cancer/neuroblastoma/detection-diagnosis-staging/signs-and-symptoms.html. Updated: January 22, 2016. Accessed: March 9, 2017.
  13. Kaplan SJ, Holbrook CT, McDaniel HG, et al. Vasoactive Intestinal Peptide Secreting Tumors of Childhood. Am J Dis Child. 1980; 134 (1): p.21-24. doi: 10.1001/archpedi.1980.02130130013005 . | Open in Read by QxMD
  14. King D, Goodman J, Hawk T, Boles ET Jr, Sayers MP. Dumbbell neuroblastomas in children.. Arch Surg. 1975; 110 (8): p.888-91.
  15. Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report. Journal of Clinical Oncology. 2009; 27 (2): p.298-303. doi: 10.1200/jco.2008.16.6876 . | Open in Read by QxMD
  16. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010; 363 (14): p.1324-1334. doi: 10.1056/NEJMoa0911123 . | Open in Read by QxMD
  17. Lo piccolo MS, Cheung NK, Cheung IY. GD2 synthase: a new molecular marker for detecting neuroblastoma. Cancer. 2001; 92 (4): p.924-931.
  18. FDA Approves First Therapy for High-Risk Neuroblastoma. https://www.cancer.gov/news-events/cancer-currents-blog/2015/dinutuximab-neuroblastoma. Updated: March 27, 2015. Accessed: February 16, 2017.
  19. Shohet JM, Nuchtern JG. Treatment and Prognosis of Neuroblastoma. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. http://www.uptodate.com/contents/treatment-and-prognosis-of-neuroblastoma.Last updated: June 30, 2016. Accessed: February 16, 2017.
  20. Neuroblastoma Risk Groups: Children's Oncology Group (COG) risk groups. https://www.cancer.org/cancer/neuroblastoma/detection-diagnosis-staging/risk-groups.html. Updated: January 22, 2016. Accessed: February 16, 2017.
  21. Survival Rates for Neuroblastoma Based on Risk Groups. https://www.cancer.org/cancer/neuroblastoma/detection-diagnosis-staging/survival-rates.html. Updated: January 22, 2016. Accessed: March 9, 2017.
  22. Neuroblastoma. https://old.cancer.org/acs/groups/cid/documents/webcontent/003125-pdf.pdf. Updated: January 22, 2016. Accessed: March 9, 2017.
  23. Rajwanshi A, Srinivas R, Upasana G. Malignant small round cell tumors. J Cytol. 2009; 26 (1): p.1-10. doi: 10.4103/0970-9371.54861 . | Open in Read by QxMD